Nuwellis Aquadex registry shows 86% of pediatric cases with complete data reached planned treatment duration
NUWE•Nuwellis said 86% of pediatric Aquadex cases with complete data reached the planned treatment duration. The company will discuss ULTRA-Peds registry results at a December 1, 2026, webinar.
1. Registry results
The multicenter ULTRA-Peds study evaluated Aquadex use in critically ill infants and children. Most treatments with complete data lasted their planned duration; early circuit terminations mainly involved vascular access problems or clotting. The study was accepted for publication in Pediatric Nephrology.
2. Upcoming discussion
Nuwellis will discuss the registry results at a December 1, 2026, webinar.




